Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T18:57:56.577Z.
Calculation as of: 2026-10-06T18:57:56.577Z.
Quote observation: 2026-10-06T18:54:53.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9cbfdb9b702203632c67f1d3ce56f9042d1c779579fe07ac28526a5c99bc9a0a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$443.54M
Price/OCF Ratio
N/A
TTM Avg
15.33
3Y Avg
15.33
5Y Avg
15.33
Market Cap
$439.15M
Price/OCF Ratio
N/A
TTM Avg
3.55
3Y Avg
3.55
5Y Avg
3.55
Market Cap
$437.49M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$448.16M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$448.87M
Price/OCF Ratio
N/A
TTM Avg
1.92
3Y Avg
1.92
5Y Avg
1.92
Market Cap
$430.46M
Price/OCF Ratio
N/A
TTM Avg
250.18
3Y Avg
250.18
5Y Avg
250.18
Market Cap
$427.05M
Price/OCF Ratio
19.37
TTM Avg
23.17
3Y Avg
204.78
5Y Avg
202.88
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NeuroPace, Inc. (NPCE) | $442.20M | N/A | N/A | N/A | N/A |
| Capricor Therapeutics, Inc. (CAPR)vs › | $443.54M | N/A | 15.33 | 15.33 | 15.33 |
| Assembly Biosciences, Inc. (ASMB)vs › | $439.15M | N/A | 3.55 | 3.55 | 3.55 |
| Tectonic Therapeutic, Inc. (TECX)vs › | $437.49M | N/A | N/A | N/A | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $448.16M | N/A | N/A | N/A | N/A |
| Ovid Therapeutics Inc. (OVID)vs › | $448.87M | N/A | 1.92 | 1.92 | 1.92 |
| Editas Medicine, Inc. (EDIT)vs › | $430.46M | N/A | 250.18 | 250.18 | 250.18 |
| NRC Health (NRC)vs › | $455.38M | 15.43 | 15.15 | 16.14 | 19.77 |
| NeoGenomics, Inc. (NEO)vs › | $427.05M | 19.37 | 23.17 | 204.78 | 202.88 |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $427.50M | N/A | 98.12 | 98.12 | 98.12 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
